RxDoctor Payments Data

Sabrina Depue, PA

Surgical · Allentown, PANPI 1326774902

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.2% of the total across 171 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 52 manufacturers, the largest accounting for just 5.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,543, more than ten times the $31 reported in 2022. Among surgical clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,564in general payments, 2019–2025

Across 171 payments — averaging $20.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sobi, Inc$210
  • Gilead$208
  • Johnson & Johnson$207
  • AstraZeneca$180
  • Daiichi Sankyo Inc.$175
  • Novartis$172
  • plus $2K from 46 others

What the payments were for

  • Food & beverage$3,32193%
  • Education$2427%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,564 in reported general payments places this provider in the 90th percentile of 626 surgical providers in Pennsylvania.

See all surgical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$332,202
Medicare patients
83
Services billed
16,272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron12$6,718
Tamsulosin Hcl117$2,319
Trospium Chloride11$894
Prochlorperazine Maleate33$318
Finasteride17$303
Ondansetron Hcl29$216
Dexamethasone15$179
Oxycodone Hcl17$155
Alprazolam12$60
Prednisone13$56

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$139$6,71812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 626 surgical providers in Pennsylvania.

Other surgical in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →